Drugs News and Research

RSS

Med14 protein drives GLP-1 benefits in pancreatic beta cells

GLP-1s are building a reputation as "wonder drugs." First characterized for their ability to improve insulin release and treat diabetes, the drugs were later found to promote weight loss and improve cardiovascular health.

6 Mar 2026

Modified psilocybin compounds may treat brain disorders with fewer hallucinations

Psilocybin - the psychoactive compound in "magic mushrooms" - is gaining scientific attention for its potential in treating neuropsychiatric conditions including depression, anxiety, substance use disorders and certain neurodegenerative diseases.

6 Mar 2026

Research reveals nuclear metabolic fingerprint in human cells

More than two hundred metabolic enzymes, many of which are normally tasked with producing energy in the mitochondria, are also found sitting directly on top of human DNA, according to a study published today in Nature Communications.

6 Mar 2026

Studies highlight benefits of osseointegration for patients with limb amputations

Three new studies from Hospital for Special Surgery (HSS) highlight the use and advantages of osseointegration (OI) for individuals with an amputation, in some instances challenging prevailing beliefs about which patients would benefit.

6 Mar 2026

Engineered lettuce may turn injectable GLP-1 therapies into oral pills

Few drugs have entered mainstream awareness as quickly or as dramatically as glucagon-like peptide-1, or GLP-1 receptor agonists. Initially approved by the FDA for the treatment of type 2 diabetes, they have since also transformed the therapeutic landscape of obesity and weight management.

6 Mar 2026

Single dose of CAR-astrocyte therapy halves amyloid levels in mice brains

The new generation of Alzheimer's disease drugs - the first proven to change the course of the disease - typically extend independent living for patients by 10 months.

6 Mar 2026

New compound shows promise in protecting the liver from damage after small bowel surgery

When parts of the small intestine are diseased or die, the treatment can involve surgically removing the affected tissue.

6 Mar 2026

Six federal scientists run out by Trump talk about the work left undone

Marc Ernstoff, a physician who has pioneered immunotherapy research and treatments for cancer patients, said his work as a federal scientist proved untenable under the Trump administration.

6 Mar 2026

MSK uncovers how interacting mutations shield breast cancer

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have made an important discovery about how genetic mutations in breast cancer patients can interact and drive resistance to certain drugs called CDK4/6 inhibitors. This finding, published in Nature, suggests a new strategy for predicting and preventing resistance to specific therapies based on the tumor's genetic profile.

6 Mar 2026

Study tracks surge in leucovorin after White House promotion

A White House briefing in September 2025 that raised concerns about acetaminophen use during pregnancy and promoted the drug leucovorin as a potential autism treatment was followed by sharp changes in how doctors prescribed those medications nationwide, according to a new study.

6 Mar 2026

Mussel-inspired adhesive prevents organ rejection

A new technology has been developed to suppress immune rejection, the biggest challenge in organ transplantation, without causing systemic side effects. A research team from Pohang University of Science and Technology (POSTECH) and Ewha Womans University has developed the "Immune-Shield" technology, which directly sprays immunosuppressants onto the surface of organs using mussel-derived adhesive protein.

6 Mar 2026

A review of methionine dependency in modern cancer therapy

Methionine restriction (MR) has shown significant promise in cancer therapy because it targets the unique methionine dependency of many tumors. However, despite extensive research on MR, a clear synthesis of preclinical findings and their translation into clinical settings is lacking. This review aims to address this gap by consolidating existing evidence, identifying challenges, and highlighting opportunities for advancing MR as a viable cancer treatment strategy.

6 Mar 2026

A novel approach to improving survival in treatment-resistant cancers

Researchers at the National University of Singapore (NUS) have identified a protein called tyrosine phosphatase 1B (PTP1B) as a potential "switch" that can modulate a type of cancer cell death known as immunogenic cell death (ICD).

6 Mar 2026

Dual targeting strategy may improve treatment for resistant lung cancers

Findings from a study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) support the potential of new therapies that could improve clinical outcomes for patients with squamous and adenocarcinoma non-small cell lung cancers (NSCLC) that don't respond to immunotherapy.

5 Mar 2026

New strategy boosts immunotherapy against aggressive ovarian cancer

Cells in our immune system are best known for providing security against external invaders such as bacteria and viruses. These immune cells also guard against internal threats, including cancerous tumors.

5 Mar 2026

Drug combination shows greater weight loss while preserving muscle mass

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also preserving lean mass, such as skeletal muscle and connective tissue.

5 Mar 2026

Repurposed kidney drug finerenone shows promise in treating premature ovarian insufficiency

Premature ovarian insufficiency (POI) is a clinically significant cause of infertility that affects between 1 to 3% of women of childbearing age.

5 Mar 2026

Tufts researchers identify new vulnerabilities to combat persistent C. diff infections

Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile—commonly known as C. diff—are a serious and persistent problem for patients and hospitals alike.

5 Mar 2026

High use of anticholinergic drugs linked to increased cardiovascular disease risk

People who use drugs with anticholinergic effects, including certain antidepressants, drugs for urinary incontinence and common antihistamines, are at higher risk of developing cardiovascular disease.

5 Mar 2026

Mapping the year-one weight trajectory after stopping GLP-1s

A year after stopping taking weight loss drugs such as Ozempic and Wegovy, people regain, on average, 60% of their lost weight – but beyond this, their weight regain plateaus, with individuals managing to keep off 25% of the weight lost to treatment, say researchers at the University of Cambridge.

4 Mar 2026